ArticleJournal of ovarian research2025

Four-year complete remission with reduced-dose PARP inhibitor in advanced-stage epithelial ovarian cancer harboring a BRCA1 mutation: a case report of a chemotherapy-intolerant patient with idiopathic thrombocytopenic purpura.

Peiyao Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.